{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:59:14Z","timestamp":1785499154093,"version":"3.56.0"},"reference-count":33,"publisher":"Akademiai Kiado Zrt.","issue":"7","license":[{"start":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T00:00:00Z","timestamp":1739664000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Magyar Kutat\u00e1si H\u00e1l\u00f3zat, HUN-REN\u2013SE, Endokrin Molekul\u00e1ris Patol\u00f3giai Kutat\u00f3csoport"},{"DOI":"10.13039\/501100015498","name":"Innov\u00e1ci\u00f3s \u00e9s Technol\u00f3giai Miniszt\u00e9rium","doi-asserted-by":"crossref","award":["2020-4.1.1.-TKP2020-MOLOKRIV"],"award-info":[{"award-number":["2020-4.1.1.-TKP2020-MOLOKRIV"]}],"id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2025,2,16]]},"abstract":"R\u00e9g\u00f3ta ismert, hogy differenci\u00e1lt pajzsmirigyr\u00e1kok ut\u00e1n \u2013 az \u00e1ltal\u00e1nos\n popul\u00e1ci\u00f3hoz k\u00e9pest \u2013 gyakoribbak bizonyos m\u00e1sodik primer tumorok. Emellett\n egyes malignus betegs\u00e9gek ut\u00e1n a v\u00e1rtn\u00e1l gyakrabban fordul el\u0151 pajzsmirigyr\u00e1k\n m\u00e1sodik tumork\u00e9nt. \u00c1ttekint\u0151 k\u00f6zlem\u00e9ny\u00fcnkben bemutatjuk a differenci\u00e1lt\n pajzsmirigyr\u00e1k kapcsolat\u00e1t az egy\u00e9b primer malignus betegs\u00e9gekkel. Kit\u00e9r\u00fcnk a\n pajzsmirigyr\u00e1kok ut\u00e1n el\u0151fordul\u00f3 m\u00e1sodik primer malignit\u00e1sok gyakoris\u00e1g\u00e1ra,\n illetve elemezz\u00fck a f\u00e9rfiakban \u00e9s n\u0151kben el\u0151fordul\u00f3 leggyakoribb daganatt\u00edpusok\n ut\u00e1n kialakul\u00f3 m\u00e1sodik primer pajzsmirigyr\u00e1k rizik\u00f3j\u00e1t a leg\u00fajabb szakirodalom\n alapj\u00e1n. Mivel a kett\u0151s tumorok kialakul\u00e1s\u00e1t sz\u00e1mos t\u00e9nyez\u0151 befoly\u00e1solja \u2013\n genetikai hajlam, \u00e9letm\u00f3dbeli \u00e9s k\u00f6rnyezeti t\u00e9nyez\u0151k, az els\u0151 tumorra\n alkalmazott kezel\u00e9s, \u00e9rz\u00e9kel\u00e9si torz\u00edt\u00e1s \u2013, a m\u00e1sodik primer malignit\u00e1sok\n kock\u00e1zat\u00e1ra a k\u00fcl\u00f6nb\u00f6z\u0151 k\u00f6zlem\u00e9nyekben elt\u00e9r\u0151 \u00e9rt\u00e9keket tal\u00e1lunk. Mindezzel\n egy\u00fctt meg\u00e1llap\u00edthatjuk, hogy az \u00e1tlagn\u00e9pess\u00e9ghez k\u00e9pest pajzsmirigyr\u00e1k ut\u00e1n\n gyakoribb az eml\u0151-, prosztata-, vastagb\u00e9l-, v\u00e9gb\u00e9l- \u00e9s veser\u00e1k, valamint\n bizonyos hematol\u00f3giai malignit\u00e1sok. Pajzsmirigyr\u00e1k gyakrabban jelenik meg az\n eml\u0151-, prosztata-, vastagb\u00e9l-, v\u00e9gb\u00e9l-, t\u00fcd\u0151-, vese- \u00e9s h\u00fagyh\u00f3lyagr\u00e1k, valamint\n bizonyos hematol\u00f3giai malignit\u00e1sok \u00e9s neuroblastoma ut\u00e1n. Ezek alapj\u00e1n\n pajzsmirigyr\u00e1k ut\u00e1n hossz\u00fa klinikai k\u00f6vet\u00e9s javasolt az esetleg kialakul\u00f3\n m\u00e1sodik primer malignit\u00e1s korai felismer\u00e9s\u00e9re, a betegek r\u00e9sz\u00e9r\u0151l pedig az\n \u00e1ltal\u00e1nos n\u00e9pess\u00e9gnek aj\u00e1nlott r\u00e1ksz\u0171r\u00e9sek, illetve az el\u0151\u00edrt orvosi vizitek\n fokozott betart\u00e1sa javasolt. Orv Hetil. 2025; 166(7): 253\u2013262.<\/jats:p>","DOI":"10.1556\/650.2025.33235","type":"journal-article","created":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T04:01:17Z","timestamp":1739678477000},"page":"253-262","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":1,"title":["A differenci\u00e1lt pajzsmirigyr\u00e1k rizik\u00f3ja mint els\u0151 \u00e9s m\u00e1sodik primer tumor"],"prefix":"10.1556","volume":"166","author":[{"given":"Andr\u00e1s","family":"Kiss","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Onkol\u00f3giai Klinika Budapest, Kor\u00e1nyi S. u. 2\/a, 1083 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Szili","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Onkol\u00f3giai Klinika Budapest, Kor\u00e1nyi S. u. 2\/a, 1083 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bence","family":"Bakos","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Onkol\u00f3giai Klinika Budapest, Kor\u00e1nyi S. u. 2\/a, 1083 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1lint","family":"T\u00f3bi\u00e1s","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Onkol\u00f3giai Klinika Budapest, Kor\u00e1nyi S. u. 2\/a, 1083 Magyarorsz\u00e1g"},{"name":"HUN-REN-SE ENDOMOLPAT Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadett","family":"Balla","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Onkol\u00f3giai Klinika Budapest, Kor\u00e1nyi S. u. 2\/a, 1083 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Tak\u00e1cs","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Onkol\u00f3giai Klinika Budapest, Kor\u00e1nyi S. u. 2\/a, 1083 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Lakatos","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Onkol\u00f3giai Klinika Budapest, Kor\u00e1nyi S. u. 2\/a, 1083 Magyarorsz\u00e1g"},{"name":"HUN-REN-SE ENDOMOLPAT Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"K\u00f3sa","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Onkol\u00f3giai Klinika Budapest, Kor\u00e1nyi S. u. 2\/a, 1083 Magyarorsz\u00e1g"},{"name":"HUN-REN-SE ENDOMOLPAT Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Wang X, Zeng M, Ju X, et al. Correlation between second and first\n primary cancer: systematic review and meta-analysis of 9 million cancer patients\n [published correction appears in Br J Surg. 2024; 111(2): znae044.] Br J Surg.\n 2024; 111(1): znad377.","DOI":"10.1093\/bjs\/znae044"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Hou F, Cheng T, Yang CL, et al. Risk prediction of second primary\n malignant tumor in primary differentiated thyroid cancer patients: a\n population-based study. J Cancer Res Clin Oncol. 2023; 149:\n 12379\u201312391.","DOI":"10.1007\/s00432-023-05135-w"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Sawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk\n after radioactive iodine treatment for thyroid cancer: a systematic review and\n meta-analysis. Thyroid 2009; 19: 451\u2013457.","DOI":"10.1089\/thy.2008.0392"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Wang H, Wang Y, Yang R, et al. Risk of second primary lung cancer in\n patients with thyroid cancer: a meta-analysis based on big population studies.\n Chin Med J (Engl). 2023; 136: 1532\u20131538.","DOI":"10.1097\/CM9.0000000000002457"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Ruan X, Huang D, Zhan Y, et al. Risk of second primary cancers after\n a diagnosis of first primary cancer: a pan-cancer analysis and Mendelian\n randomization study. Elife 2023; 12: e86379.","DOI":"10.7554\/eLife.86379"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"S\u00e1nta F, Semj\u00e9n D, Kuthi L. Hereditary renal tumor syndromes.\n [\u00d6r\u00f6kletes vesetumor-szindr\u00f3m\u00e1k.] Orv Hetil. 2023; 164: 363\u2013375.\n [Hungarian]","DOI":"10.1556\/650.2023.32729"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Turcotte LM, Neglia JP, Reulen RC, et al. Risk, risk factors, and\n surveillance of subsequent malignant neoplasms in survivors of childhood cancer:\n a review. J Clin Oncol. 2018; 36: 2145\u20132152.","DOI":"10.1200\/JCO.2017.76.7764"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Bakos B, Kiss A, \u00c1rvai K, et al. Co-occurrence of thyroid and breast\n cancer is associated with an increased oncogenic SNP burden. BMC Cancer 2021;\n 21: 706.","DOI":"10.1186\/s12885-021-08377-4"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Kim KJ, Kim KJ, Choi J, et al. Linear association between\n radioactive iodine dose and second primary malignancy risk in thyroid cancer. J\n Natl Cancer Inst. 2023; 115: 695\u2013702.","DOI":"10.1093\/jnci\/djad040"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Kim S, Bang JI, Boo D, et al. Second primary malignancy risk in\n thyroid cancer and matched patients with and without radioiodine therapy\n analysis from the observational health data sciences and informatics. Eur J Nucl\n Med Mol Imaging 2022; 49: 3547\u20133556.","DOI":"10.1007\/s00259-022-05779-9"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Reinecke MJ, Ahlers G, Burchert A, et al. Second primary\n malignancies induced by radioactive iodine treatment of differentiated thyroid\n carcinoma. A critical review and evaluation of the existing evidence. Eur J Nucl\n Med Mol Imaging 2022; 49: 3247\u20133256.","DOI":"10.1007\/s00259-022-05762-4"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Pasqual E, Schonfeld S, Morton LM, et al. Association between\n radioactive iodine treatment for pediatric and young adulthood differentiated\n thyroid cancer and risk of second primary malignancies. J Clin Oncol. 2022; 40:\n 1439\u20131449. Erratum: J Clin Oncol. 2022; 40: 2283.","DOI":"10.1200\/JCO.21.01841"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Zhao X, Chen M, Qi X, et al. Association of radioiodine for\n differentiated thyroid cancer and second breast cancer in female adolescent and\n young adult. Front Endocrinol (Lausanne) 2022; 12: 805194.","DOI":"10.3389\/fendo.2021.805194"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Tan H, Wang S, Huang F, et al. Association between breast cancer and\n thyroid cancer risk: a two-sample Mendelian randomization study. Front\n Endocrinol (Lausanne) 2023; 14: 1138149.","DOI":"10.3389\/fendo.2023.1138149"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Goldgar DE, Easton DF, Cannon-Albright, et al. Systematic\n population-based assessment of cancer risk in first-degree relatives of cancer\n probands. J Natl Cancer Inst. 1994; 86: 1600\u20131608.","DOI":"10.1093\/jnci\/86.21.1600"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Lu M, Liu H, Zheng B, et al. Links between breast and thyroid\n cancer: hormones, genetic susceptibility and medical interventions. Cancers\n (Basel) 2022; 14: 5117.","DOI":"10.3390\/cancers14205117"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Choi WJ, Kim J. Dietary factors and the risk of thyroid cancer: a\n review. Clin Nutr Res. 2014; 3: 75\u201388.","DOI":"10.7762\/cnr.2014.3.2.75"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Allen I, Hassan H, Sofianopoulou E, et al. Risks of second\n non-breast primaries following breast cancer in women: a systematic review and\n meta-analysis. Breast Cancer Res. 2023; 25: 18.","DOI":"10.1186\/s13058-023-01610-x"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Allen I, Hassan H, Sofianopoulou E, et al. Risk of developing a\n second primary cancer in male breast cancer survivors: a systematic review and\n meta-analysis. Br J Cancer 2022; 127: 1660\u20131669.","DOI":"10.1038\/s41416-022-01940-1"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Wu Y, Li Y, Han C, et al. Risk of second primary malignancies\n associated with radiotherapy in prostate cancer patients: competing risk\n analysis. Future Oncol. 2022; 18: 445\u2013455.","DOI":"10.2217\/fon-2021-0332"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Chattopadhyay S, Zheng G, Hemminki O, et al. Prostate cancer\n survivors: risk and mortality in second primary cancers. Cancer Med. 2018; 7:\n 5752\u20135759.","DOI":"10.1002\/cam4.1764"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Du S, Li Y, Sun H, et al. The risk of developing second primary\n malignancies among colorectal cancer patients. Aging (Albany NY) 2022; 14:\n 6756\u20136779.","DOI":"10.18632\/aging.204250"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Robertson D, Ng SK, Baade PD, et al. Risk of extracolonic second\n primary cancers following a primary colorectal cancer: a systematic review and\n meta-analysis. Int J Colorectal Dis. 2022; 37: 541\u2013551.","DOI":"10.1007\/s00384-022-04105-x"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Su VY, Liu CJ, Chen YM, et al. Risk of second primary malignancies\n in lung cancer survivors. The influence of different treatments. Target Oncol.\n 2017; 12: 219\u2013227.","DOI":"10.1007\/s11523-016-0459-0"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Bengtsen MB, Farkas DK, S\u00f8rensen HT, et al. Renal cell carcinoma and\n risk of second primary cancer. A Danish nationwide cohort study. Cancer Med.\n 2024; 13: e7237.","DOI":"10.1002\/cam4.7237"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Khanal A, Budhathoki N, Singh VP, et al. Second primary malignancy\n in bladder carcinoma. A population-based study. Anticancer Res. 2017; 37:\n 2033\u20132036.","DOI":"10.21873\/anticanres.11548"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Kwon WA, Joung JY, Lim J, et al. Risk of second primary cancer among\n bladder cancer patients: a population-based cohort study in Korea. BMC Cancer\n 2018; 18: 617.","DOI":"10.1186\/s12885-018-4530-3"},{"key":"R28","unstructured":"Curtis RE, Freedman DM, Ron E, et al. (eds.) New malignancies among\n cancer survivors: SEER Cancer Registries, 1973\u20132000. National Cancer Institute,\n NIH Publ. No. 05-5302; Bethesda, MD, 2006."},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Lee KD, Chen CY, Huang HJ, et al. Increased risk of second primary\n malignancies following uterine cancer: a population-based study in Taiwan over a\n 30-year period. BMC Cancer 2015; 15: 393.","DOI":"10.1186\/s12885-015-1426-3"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Schaapveld M, Aleman BM, van Eggermond AM, et al. Second cancer risk\n up to 40 years after treatment for Hodgkin\u2019s lymphoma. N Engl J Med. 2015; 373:\n 2499\u20132511.","DOI":"10.1056\/NEJMoa1505949"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Brabrand M, Frederiksen H. Risks of solid and lymphoid malignancies\n in patients with myeloproliferative neoplasms: clinical implications. Cancers\n (Basel) 2020; 12: 3061.","DOI":"10.3390\/cancers12103061"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Westerveld ASR, van Dalen EC, Asogwa OA, et al. Neuroblastoma\n survivors at risk for developing subsequent neoplasms: a systematic review.\n Cancer Treat Rev. 2022; 104: 102355.","DOI":"10.1016\/j.ctrv.2022.102355"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Gilitsch A, Vojcek \u00c1, Mez\u0151si E, et al.\n 131-I-meta-iodo-benzyl-guanidine therapy in childhood neuroblastoma: first\n experiences in Hungary. [Gyermekkori neuroblastoma kezel\u00e9s\u00e9ben alkalmazott\n 131-I-meta-jodo-benzil-guanidin ter\u00e1pia: els\u0151 hazai tapasztalatok.] Orv Hetil.\n 2023; 164: 1550\u20131555. [Hungarian]","DOI":"10.1556\/650.2023.32870"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/166\/7\/article-p253.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/166\/7\/article-p253.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/166\/7\/article-p253.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:23:38Z","timestamp":1785497018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/166\/7\/article-p253.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,16]]},"references-count":33,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.1556\/650.2025.33235","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,16]]}}}